EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Bridging tumor growth dynamics and survival in preclinical oncology drug development – a Tumor Growth Inhibition and Time-to-Event (TGI-TTE) modeling framework

Kumar Kulldeep Niloy, Jamie Horn, Nazmul Hasan Bhuiyan, Suhas S Bhosale, Khaled A Shaaban, Thomas E Prisinzano, Jon S Thorson, Jurgen Rohr, Markos Leggas iD

Cancer Chemotherapy and Pharmacology · 2026

DOI: 10.1007/s00280-026-04947-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2026. Verfasst von Kumar Kulldeep Niloy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA. Hauptthemen laut MEDLINE: Sarcoma, Ewing, Antineoplastic Agents, Drug Development, Models, Biological. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NCATS NIH HHS, NIH/NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To develop a tumor growth inhibition and time-to-event (TGI-TTE) modeling framework linking drug exposure, tumor dynamics, and survival. Modeling used preclinical efficacy studies with MTMSA-Trp, a preclinical-stage anti-tumor agent for Ewing sarcoma.

Methods

Tumor volume and survival data from Ewing sarcoma mouse xenografts treated with MTMSA-Trp (0.3–2.85 mg/kg) were analyzed. A Simeoni TGI model was used to estimate individual exponential and linear tumor growth rates. A parametric log-logistic TTE model was used to describe mouse survival across treatment groups by incorporating post hoc TGI metrics and regimen-specific average concentrations derived from the PK model as covariates associated with the model-derived event-time distribution. Models were evaluated using the precision of parameter estimates, goodness-of-fit plots, and bootstraps.

Results

The TGI model accurately described individual tumor growth dynamics, yielding precise parameter estimates (RSEs < 15%). The final TTE model successfully captured the observed Kaplan-Meier curves across treatment groups (RSEs < 20%). As expected from the endpoint definition, higher regimen-specific average concentration corresponded to longer model-derived survival (coefficient = 0.63), whereas higher exponential and linear tumor growth rates corresponded to shorter model-derived survival (coefficients = − 0.75 and − 0.46, respectively).

Conclusion

This framework quantitatively links tumor dynamics, drug exposure, and survival and may support the design, analysis, and simulation-based evaluation of dose regimens in preclinical oncology studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoma, EwingAntineoplastic AgentsDrug DevelopmentModels, BiologicalBone NeoplasmsAnimalsMiceHumansXenograft Model Antitumor AssaysFemaleTumor BurdenTime Factors

Stichwörter der Autor:innen

Ewing sarcomaMithramycin analoguesTime-to-Event ModelingTumor growth inhibition modeling

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Department of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN, USA.
  • Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, USA.
  • Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, USA.
  • Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA. mark.leggas@stjude.org.
  • Center for Translational Pharmacology, St. Jude Children's Research Hospital, Memphis, TN, USA. mark.leggas@stjude.org.

ORCID-Profile: Markos Leggas

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS
  • NIH/NCI
  • NCI NIH HHS
  • USDA-NIFACBGP
  • Markey Cancer Center, University of Kentucky
  • NIH
  • National Center for Advancing Translational Sciences

Zitieren

APA

Niloy, K. K., Horn, J., Bhuiyan, N. H., Bhosale, S. S., Shaaban, K. A., Prisinzano, T. E., Thorson, J. S., Rohr, J., & Leggas, M. (2026). Bridging tumor growth dynamics and survival in preclinical oncology drug development – a Tumor Growth Inhibition and Time-to-Event (TGI-TTE) modeling framework. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-026-04947-0

Vancouver

Niloy KK, Horn J, Bhuiyan NH, Bhosale SS, Shaaban KA, Prisinzano TE, et al. Bridging tumor growth dynamics and survival in preclinical oncology drug development – a Tumor Growth Inhibition and Time-to-Event (TGI-TTE) modeling framework. Cancer Chemotherapy and Pharmacology. 2026. doi:10.1007/s00280-026-04947-0

BibTeX
@article{Niloy2026,
  author = {Niloy, Kumar Kulldeep and Horn, Jamie and Bhuiyan, Nazmul Hasan and Bhosale, Suhas S and Shaaban, Khaled A and Prisinzano, Thomas E and Thorson, Jon S and Rohr, Jurgen and Leggas, Markos},
  title = {Bridging tumor growth dynamics and survival in preclinical oncology drug development – a Tumor Growth Inhibition and Time-to-Event (TGI-TTE) modeling framework},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  doi = {10.1007/s00280-026-04947-0}
}
Kostenlos starten →